Research Analysts Issue Forecasts for SPRY Q3 Earnings

Key Points

• Roth Capital forecasts ARS Pharmaceuticals will report Q3 2025 earnings per share of ($0.44), maintaining a "Buy" rating with a price target of $40.00.
• The company recently announced a Q2 loss of ($0.46) EPS, missing expectations, but had revenue of $15.72 million, surpassing estimates of $12.92 million.
• Insider trading activity showed CFO Kathleen D. Scott sold shares significantly, reducing her position by 55.45%, raising questions about management sentiment towards the stock.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at Roth Capital issued their Q3 2025 earnings per share estimates for ARS Pharmaceuticals in a note issued to investors on Thursday, September 4th. Roth Capital analyst J. Wittes forecasts that the company will post earnings per share of ($0.44) for the quarter. Roth Capital currently has a "Buy" rating and a $40.00 price target on the stock. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. Roth Capital also issued estimates for ARS Pharmaceuticals' Q4 2025 earnings at ($0.38) EPS, FY2025 earnings at ($1.63) EPS, Q1 2026 earnings at ($0.35) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $0.77 EPS, FY2028 earnings at $2.06 EPS and FY2029 earnings at $4.06 EPS.

Separately, Wall Street Zen downgraded ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, July 26th. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat, ARS Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $32.50.

ARS Pharmaceuticals Price Performance

ARS Pharmaceuticals stock traded down $0.06 during midday trading on Monday, reaching $10.09. The company's stock had a trading volume of 272,981 shares, compared to its average volume of 1,704,696. ARS Pharmaceuticals has a fifty-two week low of $9.97 and a fifty-two week high of $18.90. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.98 and a current ratio of 6.17. The stock's 50 day simple moving average is $15.40 and its 200 day simple moving average is $14.32. The firm has a market capitalization of $996.90 million, a PE ratio of -20.57 and a beta of 0.87.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.05). ARS Pharmaceuticals had a negative return on equity of 21.85% and a negative net margin of 42.74%.The company had revenue of $15.72 million for the quarter, compared to analyst estimates of $12.92 million.

Insiders Place Their Bets

In other news, insider Eric Karas sold 15,000 shares of the firm's stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $16.00, for a total value of $240,000.00. Following the completion of the transaction, the insider owned 7,696 shares in the company, valued at $123,136. This trade represents a 66.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Kathleen D. Scott sold 12,500 shares of the firm's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $15.00, for a total value of $187,500.00. Following the completion of the transaction, the chief financial officer owned 10,042 shares of the company's stock, valued at approximately $150,630. This represents a 55.45% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 882,649 shares of company stock valued at $15,773,760. Company insiders own 33.50% of the company's stock.

Institutional Trading of ARS Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bernard Wealth Management Corp. purchased a new stake in ARS Pharmaceuticals during the 4th quarter worth about $27,000. ANTIPODES PARTNERS Ltd purchased a new stake in ARS Pharmaceuticals during the 1st quarter worth about $37,000. GAMMA Investing LLC increased its position in ARS Pharmaceuticals by 4,319.7% during the 1st quarter. GAMMA Investing LLC now owns 3,359 shares of the company's stock worth $420,000 after purchasing an additional 3,283 shares in the last quarter. PNC Financial Services Group Inc. increased its position in ARS Pharmaceuticals by 78,100.0% during the 1st quarter. PNC Financial Services Group Inc. now owns 3,910 shares of the company's stock worth $49,000 after purchasing an additional 3,905 shares in the last quarter. Finally, Osaic Holdings Inc. increased its position in ARS Pharmaceuticals by 52.8% during the 2nd quarter. Osaic Holdings Inc. now owns 5,215 shares of the company's stock worth $91,000 after purchasing an additional 1,803 shares in the last quarter. Hedge funds and other institutional investors own 68.16% of the company's stock.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.